Sitewide
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research.Researchers evaluated 87 women enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study.
Similar Articles On This Topic:
- Drug prevents bone loss side effects of breast cancer medication
- Study: Osteoporosis drug reduces bone loss, tumor size in oral cancer
- Walking prevents bone loss caused from prostate cancer treatment
- After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose
- Cedars-Sinai research shows antibiotic prevents ibs symptoms for weeks after final dose
Popular Today:
Science 2.0:
- Science Can Save Crops, Forests And Endangered Animals By Doing This One Thing
- Organic Carbon In Meteorites Came From Mars
- Is That A Dragon In Your Berth Or Are You Just Happy To See Me?
- Are Anthropogenic Pressures Increasing The Speed Of Bacterial Evolution?
- From Towel Day To SpaceX And Transparency Grenades
Recent Articles:
Read Us On Your Kindle:
Create Your Own Releases:
Post new comment